Quantcast
ZME Science
  • CoronavirusNEW
  • News
  • Environment
    • Climate
    • Animals
    • Renewable Energy
    • Eco tips
    • Environmental Issues
    • Green Living
  • Health
    • Alternative Medicine
    • Anatomy
    • Diseases
    • Genetics
    • Mind & Brain
    • Nutrition
  • Future
  • Space
  • Feature
    • Feature Post
    • Art
    • Great Pics
    • Design
    • Fossil Friday
    • AstroPicture
    • GeoPicture
    • Did you know?
    • Offbeat
  • More
    • About
    • The Team
    • Advertise
    • Contribute
    • Our stance on climate change
    • Privacy Policy
    • Contact
No Result
View All Result
ZME Science

No Result
View All Result
ZME Science
No Result
View All Result
Home Health & Medicine

Universal cancer vaccine could be on the horizon

Researchers want to approach cancer like an infectious disease.

Jordan Strickler by Jordan Strickler
October 3, 2019
in Health & Medicine, Science

Could RNA errors prove to be a prevention for cancer? Scientist Stephen Albert Johnston and his team at Arizona State University’s Biodesign Institute (ASU) think maybe it could. After a decade’s research, he and his team believe they might have found the answer to a universal vaccine to prevent cancer.

Johnson says that the mindset is simple: treat cancer just like an infectious disease. So, when his team looked deep within tumors, they found 200,000 cancer neoantigens — the components of cancer vaccines — that had been missed by other scientists. They also found that enough of these neoantigens occurred repeatedly in different tumors that it might be possible to make one vaccine for all tumors.

The source of these neoantigens? RNA errors of tumors, which involve changing the reading of the coding for proteins. Johnston said in cancer cells, levels of information transfer from DNA to RNA to protein become more error-prone.

ADVERTISEMENT

“We proposed that these mistakes made in cancer cells may also be the source to make a cancer vaccine,” he said.

The erroneously produced proteins are called frameshift peptides. To try to ID these frameshift and slicing mutations, the ASU team designed an array of possible frameshift peptides and were able to determine those that are unique to an individual or shared by specific tumor types. From there, they could then pick vaccine candidates. In studies on mice, the vaccines showed promise in fending off tumors.

The ASU study examined mutations in more than 50 cancer cell lines, and 85 tissue samples from Mayo Clinic Arizona cancer patients, as well as the blood from patients from five different late-stage cancer types: lung, breast, brain, gastric and pancreatic cancers.

“Personal cancer vaccines are complicated and expensive,” said Johnston. “Also, only about 40 percent of tumors have enough mutations in the DNA to make a vaccine from. We discovered that even ‘cold tumors’ at the DNA level make lots of mistakes at the RNA level. And the mistakes we focus on are frameshift peptides which are much more immunogenic than the point mutations used in personal cancer vaccines. Most importantly, we can make off-the shelf vaccines for therapeutic or even preventative vaccines which will be much less expensive.”

All of the frameshift alterations, identification and screening experiments allowed them to choose the top vaccine candidates. These were tested in several mouse studies in a variety of cancer prevention and therapy challenges.

ADVERTISEMENT

The researchers found that these vaccines could all significantly delay or even prevent tumor growth. However, the most important discovery from the mouse vaccine challenges were that pooling multiple frameshift peptides produced a significant additive increase in delaying tumor growth, and made for a more effective vaccine.

Get more science news like this...

Join the ZME newsletter for amazing science news, features, and exclusive scoops. More than 40,000 subscribers can't be wrong.

   

Johnston said they have the technology to make the human vaccine right now, but even optimistically it would be five to 10 years before human use.

“This is probably the only approach to a broadly preventative cancer vaccine, so we feel we have to try it,” said Johnston. “The implications of success would be quite large.”

The findings appeared in the journal Nature Scientific Reports.

Tags: cancervaccine
Jordan Strickler

Jordan Strickler

A space nerd and self-described grammar freak (all his Twitter posts are complete sentences), he loves learning about the unknown and figures that if he isn’t smart enough to send satellites to space, he can at least write about it. Twitter: @JordanS1981

Follow ZME on social media

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
  • Coronavirus
  • News
  • Environment
  • Health
  • Future
  • Space
  • Feature
  • More

© 2007-2019 ZME Science - Not exactly rocket science. All Rights Reserved.

No Result
View All Result
  • Coronavirus
  • News
  • Environment
    • Climate
    • Animals
    • Renewable Energy
    • Eco tips
    • Environmental Issues
    • Green Living
  • Health
    • Alternative Medicine
    • Anatomy
    • Diseases
    • Genetics
    • Mind & Brain
    • Nutrition
  • Future
  • Space
  • Feature
    • Feature Post
    • Art
    • Great Pics
    • Design
    • Fossil Friday
    • AstroPicture
    • GeoPicture
    • Did you know?
    • Offbeat
  • More
    • About
    • The Team
    • Advertise
    • Contribute
    • Our stance on climate change
    • Privacy Policy
    • Contact

© 2007-2019 ZME Science - Not exactly rocket science. All Rights Reserved.